• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
ArticleReason for exclusion
Bansback N, Ara R, Karnon J, Anis A. Economic evaluations in rheumatoid arthritis: a critical review of measures used to define health states. Pharmacoeconomics 2008;26:395–408.Review of clinical measures in rheumatoid arthritis
Bansback NJ, Brennan A, Ghatnekar O. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. Ann Rheum Dis 2005;64:995–1002.Population
Barton P, Jobanputra P, Wilson J, Bryan S, Burls A. The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis. Health Technol Assess 2004;8(11).Population
Bullano MF, McNeeley BJ, Yu YF, Quimbo R, Burawski LP, Yu EB, et al. Comparison of costs associated with the use of etanercept, infliximab, and adalimumab for the treatment of rheumatoid arthritis. Manag Care Interface 2006;19:47–53.Population
Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006;10(42).Population
Chiou C-F, Choi J, Reyes CM. Cost-effectiveness analysis of biological treatments for rheumatoid arthritis. Expert Rev Pharmacoecon Outcomes Res 2004;4:307–15.Population
Davies A, Cifaldi MA, Segurado OG, Weisman MH. Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis. J Rheumatol 2009;36:16–25.Population
Doan QV, Chiou C-F, Dubois RW. Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis. J Manag Care Pharm 2006;12:555–69.Review of TNF inhibitors in rheumatoid arthritis
Kamal KM, Miller L-A, Kavookjian J, Madhavan S. Alternative decision analysis modeling in the economic evaluation of tumur necrosis factor inhibitors for rheumatoid arthritis. Semin Arthritis Rheum 2006;36:50–60.Review of decision modelling in economic evaluations of TNF inhibitors in rheumatoid arthritis
Kobelt G, Jonsson L, Young A, Eberhardt K. The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology 2003;42:326–35.Population
Kobelt G, Eberhardt K, Geborek P. TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with Ra treated with etanercept or infliximab in southern Sweden. Ann Rheum Dis 2004;63:4–10.Population
Launois R, Payet S, Saidenberg-Kermanac'h N, Francesconi C, Franca LR, Boissier M-C. Budget impact model of rituximab after failure of one or more TNFalpha inhibitor therapies in the treatment of rheumatoid arthritis. Joint Bone Spine 2008;75:688–95.Design
Lyseng-Williamson KA, Foster RH. Infliximab: a pharmacoeconomic review of its use in rheumatoid arthritis. Pharmacoeconomics 2004;22:107–132.Population
Lyseng-Williamson KA, Plosker GL. Etanercept: a pharmacoeconomic review of its use in rheumatoid arthritis. Pharmacoeconomics 2004;22:1071–95.Population
Merkesdal S, Ruof J, Mittendorf T, Zeidler H. Cost-effectiveness of TNF-A-blocking agents in the treatment of rheumatoid arthritis. Expert Opin Pharmacother 2004;5:1881–6.Review of TNF inhibitors in rheumatoid arthritis
Monteiro RDC, Zanini AC. Cost analysis of drug therapy in rheumatoid arthritis. Braz J Pharm Sci 2008;44:25–33.Population
Muller-Ladner U. Cost effectiveness of biologics in the treatment of rheumatoid arthritis. Internist 2004;45:1402–6.Population
Nuijten MJ, Engelfriet P, Duijn K, Bruijn G, Wierz D, Koopmanschap M. A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis. Pharmacoeconomics 2001;19:1051–64.Population
Prokes M. Effectiveness of TNF antagonists in routine clinical practice and costs. Vnitr Lek 2009;55:45–53.Population
Ravasio R, Lucioni C. Economic evaluation of etanercept in AR. Pharmacoeconomics – Italian Research Articles 2006;8:129–40.Review of etanercept
Regier DA, Bansback N, Dar SA, Marra CA. Cost-effectiveness of tumor necrosis factor-alpha antagonist in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Expert Rev Pharmacoecon Outcomes Res 2007;7:155–69.Review of TNF inhibitors in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
Rubio-Terres C, Ordovas Baines JP, Pla PR, Martinez NC, Sanchez Garre MJ, Rosado Souviron MA. Use and cost of biological disease -modifying anti-rheumatic drugs in Spain (PRAXIS study). Farm Hosp 2007;31:78–92.Population
Rubio-Terres C, Ordovas Baines JP, Pla PR. Critical analyis of the article: Use and cost of biological diseasemodifying anti-rheumatic drugs in Spain (PRAXIS study). Farm Hosp 2008;32:190–3.Population
Suka M, Yoshida K. [Economic evaluation of a new treatment for rheumatoid arthritis.] Nippon Rinsho 2007;65:1327–30.Population
Tsutani K, Igarashi A. [Anti-rheumatoid biologics and pharmacoeconomic evaluation.] Nippon Rinsho 2005;63:711–18.Design
Unit of Health Economics and Technology Assessment. Rituximab in patients with rheumatoid arthritis:systematic review and economic evaluation. Budapest: Unit of Health Economics and Technology Assessment in Health Care (HUNHTA); 2006.Population
Van Den Hout WB, Goekoop-Ruiterman YPM, Allaart CF, Vries-Bouwstra JKD, Hazes JMM, Kerstens PJSM, et al. Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis. Arthritis Care Res (Hoboken) 2009;61:291–9.Population
Virkki LM, Konttinen YT, Peltomaa R, Suontama K, Saario R, Immonen K, et al. Cost-effectiveness of infliximab in the treatment of rheumatoid arthritis in clinical practice. Clin Exp Rheumatol 2008;26:1059–66.Population
Wailoo AJ, Bansback N, Brennan A, Michaud K, Nixon RM, Wolfe F. Biologic drugs for rheumatoid arthritis in the medicare program: a cost-effectiveness analysis. Arthritis Rheum 2008;58:939–46.Population
Walsh CAE, Minnock P, Slattery C, Kennedy N, Pang F, Veale DJ, et al. Quality of life and economic impact of switching from established infliximab therapy to adalimumab in patients with rheumatoid arthritis. Rheumatology 2007;46:1148–52.Population
Wong JB, Singh G, Kavanaugh A. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. Am J Med 2002;113:400–8.Population
Wong JB. Cost-effectiveness of anti-tumor necrosis factor agents. Clin Exp Rheumatol 2004;22:S65–S70.Review of TNF inhibitors in rheumatoid arthritis
Wu EQ, Chen L, Birnbaum H, Yang E, Cifaldi M. Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data. Curr Med Res Opin 2007;23:1749–59.Population

From: Appendix 5, Cost-effectiveness: table of excluded studies with rationale

Cover of Adalimumab, Etanercept, Infliximab, Rituximab and Abatacept for the Treatment of Rheumatoid Arthritis After the Failure of a Tumour Necrosis Factor Inhibitor: A Systematic Review and Economic Evaluation
Adalimumab, Etanercept, Infliximab, Rituximab and Abatacept for the Treatment of Rheumatoid Arthritis After the Failure of a Tumour Necrosis Factor Inhibitor: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 15.14.
Malottki K, Barton P, Tsourapas A, et al.
© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.